Drug
Sapanisertib clinical trials
Also written MLN0128 and INK128.
- studies test it
- 46
- open now
- 3
- in phase 3
- 0
- first study started
- 2010
Keep track of what changes. Save the sapanisertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
46 studies that test it; most in 2017 (13)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 13 |
| 2018 | 6 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 27
- Phase 2
- 27
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 34
National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (7) · Millennium Pharmaceuticals, Inc. (6) · Calithera Biosciences, Inc (3) · Faeth Therapeutics (3) · Dana-Farber Cancer Institute (2) · Imperial College London (1) · Avera McKennan Hospital & University Health Center (1)
Often tested with
Tested in the same studies.
Serabelisib (7) · Paclitaxel (6) · MLN 8237 (4) · Nivolumab (2) · Osimertinib (2) · Adavosertib (1) · Afatinib (1) · Binimetinib (1)
Studies
Open first, then newest update. How each study uses sapanisertib is read from its arms, and is right about nine times in ten.
Testing it · 46
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialRecruitingPhase 1/2National Cancer Institute (NCI)NCT06811116Written as Sapanisertib
- Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerRecruitingPhase 1/2Faeth TherapeuticsNCT07558733Written as Sapanisertib
- Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerRecruitingPhase 2Faeth TherapeuticsNCT06463028Written as Sapanisertib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Sapanisertib
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02142803Written as Sapanisertib
- Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03047213Written as Sapanisertib
- Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02503722Written as Sapanisertib
- Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04250545Written as Sapanisertib
- Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06390865Written as Sapanisertib
- Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06385496Written as Sapanisertib
- Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT04479306Written as Sapanisertib
- Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT02159989Written as Sapanisertib
- A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerTerminatedPhase 2Faeth TherapeuticsNCT05275673Written as sapanisertib
- Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT02484430Written as Sapanisertib
- Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedPhase 2Imperial College LondonNCT03648489Written as TAK228
- Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid TumorsCompletedPhase 1Avera McKennan Hospital & University Health CenterNCT03154294Written as TAK-228
- Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell CarcinomaCompletedPhase 2Bradley A. McGregor, MDNCT03097328Written as TAK-228
- Sapanisertib Before and After Surgery in Treating Patients With Recurrent GlioblastomaTerminatedPhase 1National Cancer Institute (NCI)NCT02133183Written as Sapanisertib
- A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid CancerCompletedPhase 1/2Dana-Farber Cancer InstituteNCT02244463Written as MLN0128
- Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT02893930Written as Sapanisertib
See all 46 studies that test sapanisertib →
Given in every arm · 4 — sapanisertib is usual care beside what is tested
- Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast CancerCompletedPhase 2Calithera Biosciences, IncNCT02049957Written as Sapanisertib
- Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)WithdrawnPhase 2SWOG Cancer Research NetworkNCT04267913Written as Sapanisertib
- A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02412722Written as Sapanisertib
- Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT01351350Written as MLN0128
Codes
What other systems call sapanisertib · ClinicalTrials.gg INT006065
- MeSH (NLM) C572449sapanisertibOne source NLM
- UNII (FDA) JGH0DF1U03SAPANISERTIBConfirmed FDA, NLM, Wikidata
- RxNorm 2395271One source FDA
- Wikidata Q27078072sapanisertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90548SapanisertibOne source FDA
- DrugBank DB11836One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572449 | sapanisertib | One source NLM |
| UNII (FDA) | JGH0DF1U03 | SAPANISERTIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2395271 | — | One source FDA |
| Wikidata | Q27078072 | sapanisertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90548 | Sapanisertib | One source FDA |
| DrugBank | DB11836 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.